1.

(Supplement Table S2) Results of 230Th/U-dating

2.

(Supplement Table S2) Results of 230Th/U-dating

3.

(Supplement Table S2) Results of 230Th/U-dating

4.

(Supplement Table S2) Results of 230Th/U-dating

5.

(Supplement Table S2) Results of 230Th/U-dating

6.

(Supplement Table S2) Results of 230Th/U-dating

7.

(Supplement Table S2) Results of 230Th/U-dating

8.

(Supplement Table S2) Results of 230Th/U-dating

9.

(Supplement Table S2) Results of 230Th/U-dating

1.

Validity and Reliability of the Reflux Sign Assessment.

2.

Validity and Reliability of the Reflux Sign Assessment.

3.

Validity and Reliability of the Reflux Sign Assessment.

4.

Validity and Reliability of the Reflux Sign Assessment.

1.

L'etude clinique du mois. NAVIGATOR: essai de prevention des complications cardio-vasculaires et du diabete de type 2 par le valsartan et/ou le nateglinide. ; NAVIGATOR: A trial of...

2.

L'etude clinique du mois. NAVIGATOR: essai de prevention des complications cardio-vasculaires et du diabete de type 2 par le valsartan et/ou le nateglinide. ; NAVIGATOR: A trial of...

3.

L'etude clinique du mois. NAVIGATOR: essai de prevention des complications cardio-vasculaires et du diabete de type 2 par le valsartan et/ou le nateglinide. ; NAVIGATOR: A trial of...

4.

L'etude clinique du mois. NAVIGATOR: essai de prevention des complications cardio-vasculaires et du diabete de type 2 par le valsartan et/ou le nateglinide. ; NAVIGATOR: A trial of...

1.

Table_1_A survey-based assessment of rates and covariates of mpox diagnosis and vaccination provides evidence to refine eligibility criteria for mpox vaccination among gay, bisexua...

2.

Table_1_A survey-based assessment of rates and covariates of mpox diagnosis and vaccination provides evidence to refine eligibility criteria for mpox vaccination among gay, bisexua...

3.

Table_1_A survey-based assessment of rates and covariates of mpox diagnosis and vaccination provides evidence to refine eligibility criteria for mpox vaccination among gay, bisexua...

4.

Table_1_A survey-based assessment of rates and covariates of mpox diagnosis and vaccination provides evidence to refine eligibility criteria for mpox vaccination among gay, bisexua...

5.

Table_1_A survey-based assessment of rates and covariates of mpox diagnosis and vaccination provides evidence to refine eligibility criteria for mpox vaccination among gay, bisexua...

6.

Table_1_A survey-based assessment of rates and covariates of mpox diagnosis and vaccination provides evidence to refine eligibility criteria for mpox vaccination among gay, bisexua...

7.

Table_1_A survey-based assessment of rates and covariates of mpox diagnosis and vaccination provides evidence to refine eligibility criteria for mpox vaccination among gay, bisexua...

8.

Table_1_A survey-based assessment of rates and covariates of mpox diagnosis and vaccination provides evidence to refine eligibility criteria for mpox vaccination among gay, bisexua...

9.

Table_1_A survey-based assessment of rates and covariates of mpox diagnosis and vaccination provides evidence to refine eligibility criteria for mpox vaccination among gay, bisexua...

1.

SST reconstruction for sediment core MD01-2414

2.

SST reconstruction for sediment core MD01-2414

3.

SST reconstruction for sediment core MD01-2414

4.

SST reconstruction for sediment core MD01-2414

1.

Coding of variables.

2.

Coding of variables.

3.

Coding of variables.

4.

Coding of variables.

1.

Characteristics of study respondents, summary of bivariate analysis and selection of variables for multivariate analysis.

2.

Characteristics of study respondents, summary of bivariate analysis and selection of variables for multivariate analysis.

3.

Characteristics of study respondents, summary of bivariate analysis and selection of variables for multivariate analysis.

4.

Characteristics of study respondents, summary of bivariate analysis and selection of variables for multivariate analysis.

1.

Summary of multivariable logistic regression analysis of risk factors for acquiring P . knowlesi infection.

2.

Summary of multivariable logistic regression analysis of risk factors for acquiring P . knowlesi infection.

3.

Summary of multivariable logistic regression analysis of risk factors for acquiring P . knowlesi infection.

4.

Summary of multivariable logistic regression analysis of risk factors for acquiring P . knowlesi infection.

1.

Effects of the amyloid precursor protein Glu693-->Gln 'Dutch' mutation on the production and stability of amyloid beta-protein.

2.

Effects of the amyloid precursor protein Glu693-->Gln 'Dutch' mutation on the production and stability of amyloid beta-protein.

3.

Effects of the amyloid precursor protein Glu693-->Gln 'Dutch' mutation on the production and stability of amyloid beta-protein.

4.

Effects of the amyloid precursor protein Glu693-->Gln 'Dutch' mutation on the production and stability of amyloid beta-protein.

5.

Effects of the amyloid precursor protein Glu693-->Gln 'Dutch' mutation on the production and stability of amyloid beta-protein.

6.

Effects of the amyloid precursor protein Glu693-->Gln 'Dutch' mutation on the production and stability of amyloid beta-protein.

7.

Effects of the amyloid precursor protein Glu693-->Gln 'Dutch' mutation on the production and stability of amyloid beta-protein.

8.

Effects of the amyloid precursor protein Glu693-->Gln 'Dutch' mutation on the production and stability of amyloid beta-protein.

9.

Effects of the amyloid precursor protein Glu693-->Gln 'Dutch' mutation on the production and stability of amyloid beta-protein.

1.

Real-Life Study of Mepolizumab in Idiopathic Chronic Eosinophilic Pneumonia.

2.

Real-Life Study of Mepolizumab in Idiopathic Chronic Eosinophilic Pneumonia.

3.

Real-Life Study of Mepolizumab in Idiopathic Chronic Eosinophilic Pneumonia.

4.

Real-Life Study of Mepolizumab in Idiopathic Chronic Eosinophilic Pneumonia.